Authorization

Pfizer Seeks FDA Approval For COVID-19 Vaccine Booster

(RTTNews) - Pfizer Inc. (PFE) is seeking an approval from the U.S. Food and Drug Administration for its booster dose of COVID-19 vaccine.

Pfizer and BioNTech SE (BNTX) said that they have initiated a supplemental Biologics License Application or sBLA to the FDA for the approval of a booster (third) dose of their COVID-19 Vaccine to prevent COVID-19 in individuals 16 years of age and older. The companies plan to complete submission of the sBLA by the end of this week.

The FDA on Monday gave full approval to Pfizer/BioNTech's COVID-19 vaccine for people age 16 and older.

The Pfizer/BioNTech vaccine, marketed as Comirnaty, has been authorized for emergency use in the US since last December for people age 16 and older. In May, the authorization was extended to those 12 and older.

Pfizer and BioNTech said Wednesday that the sBLA includes data from a Phase 3 clinical trial of 306 participants 18-55 years of age who received a booster (third) dose of COMIRNATY between 4.8 and 8 months after completing the two-dose primary regimen, with a median follow-up time of 2.6 months post-booster.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Февраль 2023    »
ПнВтСрЧтПтСбВс
 12345
6789101112
13141516171819
20212223242526
2728